ArticleTranslational stroke research2026
Thrombin Generation Capacity is Associated With Worse Outcome in r-tPA Treated Patients With Stroke.
Article in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant tissue plasminogen activator (r-tPA) remains the cornerstone of reperfusion therapy in patients with stroke. However, response to r-tPA is highly variable and not fully explained by clinical factors with many patients not achieving a good outcome despite thrombolysis treatment. In 78 patients with acute ischemic stroke treated with r-tPA, thrombin generation capacity was measured in plasma. Functional outcome was assessed at 90 days using the modified Rankin Scale (mRS). In addition, inflammatory markers were analyzed to identify factors associated with increased thrombin generation in this patient population. Thrombin generation capacity was significantly greater in patients with worse 90-day mRS (mRS > 2) compared to those with good 90-day mRS (mRS ≤ 2; 254 nM vs. 210 nM; p = 0.0007). This association remained significant after adjustment for admission NIHSS, age, sex, stroke etiology, and atrial fibrillation (OR: 1.68, 95% CI: 1.10-2.58; p = 0.017). In vitro, increased thrombin was associated with denser fibrin clot structure and prolonged clot lysis time in response to tPA. In patients, peak thrombin levels correlated positively with inflammatory and coagulation markers, including interleukin (IL)-6 (r = 0.421, p = 0.009), IL-8 (r = 0.382, p = 0.018), and fibrinogen (r = 0.415, p = 0.02), and inversely with α2-macroglobulin (α2M; r=-0.327, p = 0.048). Elevated thrombin generation is associated with worse outcomes in patients with acute ischemic stroke treated with r-tPA. This procoagulant state may promote formation of denser, thrombolysis-resistant thrombi and help explain interindividual variability in outcome following treatment. Thrombin generation capacity may serve as a useful biomarker to improve risk stratification and predict variability in thrombolytic response.
Indexed as
Identifiers
42663856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.